Armata Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ARMP) $2.06 +0.03 (+1.48%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.99▼$2.1250-Day Range N/A52-Week Range$0.83▼$5.26Volume1,722 shsAverage Volume59,191 shsMarket Capitalization$74.47 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Armata Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside239.8% Upside$7.00 Price TargetShort InterestHealthy0.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.71) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Armata Pharmaceuticals has a forecasted upside of 239.8% from its current price of $2.06.Amount of Analyst CoverageArmata Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.90% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Armata Pharmaceuticals has recently decreased by 0.90%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARMP. Previous Next 1.1 News and Social Media Coverage News SentimentArmata Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Armata Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest3 people have searched for ARMP on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.28% of the stock of Armata Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Armata Pharmaceuticals are expected to grow in the coming year, from ($1.71) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArmata Pharmaceuticals has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.Read More ARMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARMP Stock News HeadlinesNovember 20, 2023 | americanbankingnews.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) to Post Q4 2023 Earnings of ($0.36) Per Share, HC Wainwright ForecastsNovember 15, 2023 | markets.businessinsider.comRobust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy RatingNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 15, 2023 | finance.yahoo.comArmata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate UpdatesNovember 15, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdateNovember 14, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdateNovember 6, 2023 | money.usnews.comLexeo Therapeutics Inc.October 30, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis ConferenceNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.October 19, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023October 4, 2023 | msn.comArmata Pharmaceuticals (ARMP) Price Target Increased by 14.29% to 8.16September 28, 2023 | markets.businessinsider.comArmata Pharmaceuticals: Promising Clinical Trials and New Leadership Bolster Buy RecommendationSeptember 26, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureusSeptember 21, 2023 | finance.yahoo.comArmata Pharmaceuticals to Participate in the Cantor Global Healthcare ConferenceAugust 22, 2023 | uk.news.yahoo.comArmata Pharma (ARMP) Stock Surges 130% in a Month: Here's WhyAugust 17, 2023 | finance.yahoo.comArmata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?August 15, 2023 | markets.businessinsider.comLadenburg Thalmann & Co. Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)August 14, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate UpdateAugust 14, 2023 | seekingalpha.comArmata Pharmaceuticals GAAP EPS of -$0.17, revenue of $0.98MAugust 14, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate UpdateAugust 14, 2023 | finance.yahoo.comARMP - Armata Pharmaceuticals, Inc.July 24, 2023 | benzinga.comDow Surges 150 Points; Domino's Pizza Earnings Top ExpectationsJuly 11, 2023 | msn.comArmata Pharmaceuticals gets $25M in financing and new executive chiefMay 31, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage TherapyMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Armata Pharmaceuticals (ARMP) Buy RecommendationMay 12, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate UpdateMay 11, 2023 | seekingalpha.comArmata Pharmaceuticals GAAP EPS of -$0.40, revenue of $0.79MSee More Headlines Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today11/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ARMP CUSIPN/A CIKN/A Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees72Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+230.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,920,000.00 Net Margins-1,468.73% Pretax Margin-1,468.71% Return on Equity-280.95% Return on Assets-43.82% Debt Debt-to-Equity RatioN/A Current Ratio1.67 Quick Ratio1.67 Sales & Book Value Annual Sales$5.51 million Price / Sales13.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book2.12Miscellaneous Outstanding Shares36,150,000Free Float5,241,000Market Cap$76.64 million OptionableNot Optionable Beta0.99 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Mina Pastagia M.D. (Age 48)MS, Chief Medical Officer Comp: $537.6kDr. Deborah L. Birx M.D. (Age 66)CEO & Director Dr. Wenyuan Shi Ph.D.Co-Founder & Founding ScientistMr. Richard Rychlik (Age 67)VP, Corporate Controller & Principal Financial Officer Mr. Bryan KadotaniVice President of Program Management & OperationsDr. Pierre Kyme Ph.D.Vice President of Business & Corporate DevelopmentMore ExecutivesKey CompetitorsJATT AcquisitionNYSE:JATTCASI PharmaceuticalsNASDAQ:CASITourmaline BioNASDAQ:TRMLJasper TherapeuticsNASDAQ:JSPRCentury TherapeuticsNASDAQ:IPSCView All Competitors ARMP Stock Analysis - Frequently Asked Questions Should I buy or sell Armata Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares. View ARMP analyst ratings or view top-rated stocks. What is Armata Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 12 month price targets for Armata Pharmaceuticals' stock. Their ARMP share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 239.8% from the stock's current price. View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts. Are investors shorting Armata Pharmaceuticals? Armata Pharmaceuticals saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 99,700 shares, a decline of 25.4% from the October 15th total of 133,700 shares. Based on an average daily volume of 38,800 shares, the short-interest ratio is currently 2.6 days. Currently, 0.9% of the shares of the company are sold short. View Armata Pharmaceuticals' Short Interest. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The business earned $1.23 million during the quarter, compared to analyst estimates of $0.90 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 280.95% and a negative net margin of 1,468.73%. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD). Who are Armata Pharmaceuticals' major shareholders? Armata Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSEAMERICAN:ARMP) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.